Key Points
- Director Stanley Frankel purchased 2,700 shares on December 16 at an average price of $4.70 for $12,690, raising his direct stake to 19,478 shares (a 16.09% increase), a transaction disclosed in an SEC filing.
- Precision BioSciences reported a sharp quarterly earnings miss with EPS of -$1.84 vs. a -$0.31 consensus, negligible revenue ($0.01M vs. $5.40M expected) and extremely negative profitability metrics, signaling continued near‑term operating losses.
- The stock is thinly traded with a market capitalization of about $63.25 million and a 12‑month range of $3.61–$8.82; analyst coverage is limited (2 Buys, 1 Sell) and the consensus rating is "Hold" with a consensus price target of $47.00.
Precision BioSciences, Inc. (NASDAQ:DTIL - Get Free Report) Director Stanley Frankel acquired 2,700 shares of the business's stock in a transaction dated Tuesday, December 16th. The shares were acquired at an average price of $4.70 per share, for a total transaction of $12,690.00. Following the acquisition, the director directly owned 19,478 shares in the company, valued at $91,546.60. This represents a 16.09% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.
Stanley Frankel also recently made the following trade(s):
- On Friday, September 26th, Stanley Frankel bought 2,700 shares of Precision BioSciences stock. The shares were bought at an average price of $4.97 per share, for a total transaction of $13,419.00.
Precision BioSciences Stock Up 0.2%
Shares of Precision BioSciences stock traded up $0.01 on Thursday, hitting $4.77. The company had a trading volume of 11,850 shares, compared to its average volume of 270,160. The stock has a 50-day moving average of $5.92 and a 200-day moving average of $5.22. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.45 and a quick ratio of 3.45. Precision BioSciences, Inc. has a twelve month low of $3.61 and a twelve month high of $8.82. The firm has a market capitalization of $63.25 million, a P/E ratio of -0.57 and a beta of 1.11.
Precision BioSciences (NASDAQ:DTIL - Get Free Report) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($1.84) EPS for the quarter, missing the consensus estimate of ($0.31) by ($1.53). The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $5.40 million. Precision BioSciences had a negative net margin of 11,977.36% and a negative return on equity of 233.77%. During the same period in the prior year, the firm posted ($2.25) earnings per share. Research analysts predict that Precision BioSciences, Inc. will post -1.23 earnings per share for the current year.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Precision BioSciences in a research report on Monday. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $47.00.
View Our Latest Research Report on Precision BioSciences
Institutional Investors Weigh In On Precision BioSciences
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Precision BioSciences during the 3rd quarter worth about $72,000. Virtu Financial LLC acquired a new stake in shares of Precision BioSciences in the third quarter valued at about $84,000. GSA Capital Partners LLP bought a new stake in Precision BioSciences during the third quarter worth about $98,000. Velan Capital Investment Management LP acquired a new position in Precision BioSciences during the third quarter valued at approximately $110,000. Finally, Citadel Advisors LLC bought a new position in Precision BioSciences in the third quarter valued at approximately $122,000. 37.99% of the stock is owned by institutional investors.
About Precision BioSciences
(
Get Free Report)
Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
